Together with our partners Polpharma Biologics, Bioeq AG and Teva Canada, we are very pleased that Health Canada has granted the “Notice of Compliance” for our ranibizumab biosimilar FYB201/Ranopto® in Canada.

Read more in our joint press release.

      

SocialMedia